Non-Viral Drug Delivery Systems Market(2035)

 The domain is currently dominated by the presence of small players (40%). Examples include (in alphabetical order, based in North America), Acuitas Therapeutics, XXX, XXX, Carmine Therapeutics and Sisaf. This is followed by very small players, which represent nearly 30% of the total industry players.

Moreover, the majority of small players (35%) are present within the North American and European regions, followed by very small players (24%) and mid-sized players (20%). It is interesting to note that 65% of the players were privately held firms followed by the firms (35%) which are public organizations.\

Even though non-viral drug delivery systems are being offered by players based all across the globe, most of the players engaged in this domain (52%) are headquartered in North America, followed by Europe, Asia, Middle East and North Africa, and the rest of the world. Further, a large portion (44%) of players were established between 2005 to 2015, this is followed by companies (37%) established post 2015, which could be considered as an assured entry of a greater number of players showing interest in the intracellular non-viral drug delivery domain, thereby providing a larger scope of research, development and collaboration related to the intracellular delivery of non-viral therapies.

It is worth noting that, the majority of the non-viral drug delivery systems deliver biologics (71%) intracellularly, this is followed by the technologies which deliver both small molecules and biologics (26%) intracellularly. Examples of such technologies include Biopact™, XX, DeliverEX™, XX, XX and Nuvec®.

Based on our research, it was evident that DNA (XX) and RNA (XX) was the most preferred payload to be delivered intracellularly. Majority of the technologies preferred conjugation (XX) as type of interaction with biologics to be delivered, this is followed by encapsulation (XX), co-administration (XX) and Others (XX). Further, nanoparticle (XX) was the most used type of vehicle for the delivery of therapeutic payloads to the target site followed by oligonucleotide and cell penetrating peptides, extracellular vesicles and others.

In order to outshine their proprietary offerings, developers are keen to integrate advanced technologies and innovations that can attract a wider audience

In order to determine the relative competitiveness of non-viral drug delivery systems providers, we focused on relative strength of the companies based on their portfolio strength, in terms of (type of biologics delivered and type of interaction), partnership strength (numbers of partnerships established, year-wise trend, local / international and intercontinental / intracontinental partnerships, type of partnerships, therapeutic area, payment portfolio and type of biologics delivered)

Additionally, the insights on company competitiveness have been presented in the form of a 2*2 matrix, with the company’s experience (abscissa) on the x-axis, competitiveness (ordinate) on the y-axis and type of molecule delivered on the z-axis.

As per our proprietary scoring criteria, Arcturus Therapeutics emerged as the most prominent player based on its competitiveness score. The company claims to offer XX technology. Examples of other prominent very large players in this market include (arranged in decreasing order of competitiveness) Codiak Biosciences, XXX, ethris and XXX. It is worth mentioning that the majority of the firms (XX%) in this peer group are based in North America.

Over 1,100 patents have been filed / granted for intracellular drug delivery; both industry and non-industry players are actively involved in such efforts

The increasing interest of several stakeholders in the development of intracellular drug delivery has led to the expansion of intellectual capital associated with the advancements in this domain. A number of patents have been filed by companies / individuals / organizations, engaged in this market space, in order to protect novel intellectual property generated within this field.

Majority of the patent assignees are industry players; however, over the past few years, the contribution of academic players in the overall patent filing activity has increased evidently. It is interesting to mention that since 2017, the number of filed and granted patents has increased at a CAGR of over XX%.

During our research, we observed that the majority of the patents XX (54%) related to intracellular drug delivery systems have been granted and the number of patent applications is XX (43%) followed by others which include research reports and amended patents XX (2%).

According to our proprietary patent valuation analysis (performed by taking several relevant parameters into account such as patent type, patent age, number of citations and geographical reach), nearly 1% of patents have a high relative valuation classification (Category I).

The partnership activity in this industry has witnessed a growth rate of over 57% in the past seven years; it is worth noting that majority of the deals have been signed in the last 2–3 years

Over the past few years, players engaged in the domain of non-viral drug delivery have signed various partnerships aiming for efficient intracellular delivery of drugs. During our research, we observed that the majority of the partnership deals (42%) were technology licensing deals followed by technology evaluation agreements (20%). Additionally, this market has witnessed seven instances of acquisitions and mergers in the given time period. This trend reflects that companies are continuously striving to expand their existing service offerings.

During our research, it was noticed that the maximum number of technologies in the partnership deals were focused on delivery of RNA (XX) to the target site followed by DNA (XX). Notable examples of companies delivering RNA as biologics in this market space include (in reverse chronological order) agreements signed between InnoRNA and Beigene (July 2022), Acuitas Therapeutics and XXX (May 2022) and XXX and BioNTech (April 2022).

In terms of geographical regions, the majority of the agreements related to non-viral drug delivery were signed between companies located in similar regions (32% in North America and 18% in Europe).

Driven by the increasing adoption of non-viral drug delivery technologies in the healthcare sector, we anticipate the global non-viral drug delivery systems market for healthcare to grow at an annualized rate of ~14%, till 2035

The global demand for biologics currently holds the largest share (XX%) in the non-viral drug delivery domain and is expected to show a similar trend in the coming years. Further, the nanoparticle and extracellular vesicles emerged as the star as per the BCG matrix during our research. It is also interesting to note that the polymer has a low growth rate but a higher market share. Hence, it is considered as the cash cow in the current time. The ongoing research for various types of technological modifications is expected to lead to the development of newer generation of non-viral drug delivery systems that are anticipated to hold a significant share in the future market.t

The global demand for biologics currently holds the largest share in the non-viral drug delivery domain. However, the demand for small molecules in the long term is anticipated to increase as the new advances in the medical field would soon allow the intracellular delivery of drugs orally. Hence, the market for small molecules is anticipated to grow at a rate of XX% till 2035.



Comments